Bustos GÁ

Language: Spanish
References: 21
Page: 109-113
PDF size: 167.58 Kb.

ABSTRACT

Beta-lactam antibiotics are among the most commonly prescribed drugs, grouped together based upon a shared structural feature, the beta-lactam ring. Cephalosporins cover a broad range of organism, are generally well tolerated, and are easy to administer. The classification, spectrum of activity, and pharmacology of the parenterally cephalosporins will be reviewed here.

REFERENCES

1. http://www.fda.gov/Drugs/DrugSafety

2. Mulligan ME, et al. MRSA: a consensus review of the microbiology, pathogenesis, and epidemiology with implications for prevention and management. Am J Med 1993; 94:313- 328.

3. Tomasz A. Antibiotic resistance in S. pneumoniae. Clin Infect Dis 1997; 24 Suppl 1:S85-S88.

4. Friedland IR, McCracken GH Jr. Management of infections caused by antibiotic-resistant S. pneumoniae. N Engl J Med 1994; 331:337-382.

5. Whitney CG, et al. Increasing prevalence of multidrugresistant S. pneumoniae in the United States. N Engl J Med 2000; 343:1917-1924.

6. Sabath LD. Reappraisal of the antistaphylococcal activities of first-generation and second-generation cephalosporins. Antimicrob Agents Chemother 1989; 33:407-411.

7. Pitout JD, et al. Antimicrobial resistance with focus on betalactam resistance in Gram negative bacilli. Am J Med 1997; 103:51-59.

8. Schaad UB, et al. A comparison of ceftriaxone and cefuroxime for the treatment of bacterial meningitis in children. N Engl J Med 1990; 322:141-147.

9. Bohnen JM, et al. Guidelines for clinical care: anti-infective agents for intra-abdominal infection. A Surgical Infection Society policy statement. Arch Surg 1992; 127:83-89.

10. Wexler HM, Finegold SM. In vitro activity of cefotetan compared with that of other antimicrobial agents against anaerobic bacteria. Antimicrob Agents Chemother 1988; 32:601-604.

11. Snydman DR, et al. Analysis of trends in antimicrobial resistance patterns among clinical isolates of Bacteroidesfragilis group species from 1990 to 1994. Clin Infect Dis 1996; 23 Suppl 1: S54-65.

12. Klein NC, Cunha BA. Third-generation cephalosporins. Med Clin North Am 1995; 79:705-719.

13. Steere AC. Lyme disease. N Engl J Med 1989; 321:586- 596.

14. Shiffman ML, et al. Pathogenesis of ceftriaxone-associated biliary sludge. In-vitro studies of calcium-ceftriaxone binding and solubility. Gastroenterology 1990; 99:1772-1778.

15. Sattler FR, et al. Potential for bleeding with the new betalactam antibiotics. Ann Intern Med 1986; 105:924-931.

16. Sanders WE, et al. Efficacy of cefepime in the treatment of infections due to multiply resistant Enterobacter species. Clin Infect Dis 1996; 23:454-461.

17. Yahav D, et al. Efficacy and safety of cefepime: a systematic review and meta-analisis. Lancet Infect Dis 2007; 7:338-348.

18. Noel GJ. Clinical profile of ceftobiprole, a novel beta-lactam antibiotic.ClinMicrobiol Infect 2007; 13 Suppl 2:25-29.

19. Bush K, et al. Anti-MRSA beta-lactams in development, with a focus on ceftobiprole: the first anti-MRSA beta-lactam to demonstrate clinical efficacy: Expert Opin Investig Drugs 2007; 16:419-429.

20. Willems RJ, et al. Global spread of vancomycin-resistant Enterococcus faecium from distinct nosocomial genetic complex. Emerg Infect Dis 2005; 11:821-828.

21. Bogdanovich T, et al. Antistaphylococcal activity of ceftobiprole, a new broad spectrum cephalosporin. Antimicrob Agents Chemother 2005; 49:4210-4219.